United States Patent 11,020,382 (Method Claims) Scope, Claim Construction Levers, and Landscape for Oral Crystalline Solvate “Compound 1” for Sickle Cell Disease
US Patent 11,020,382 is directed to method-of-treatment claims for sickle cell disease that require (i) an orally dosed “Compound 1” at about 1500 mg once daily and (ii) a specific crystalline solvate form defined by X-ray powder diffraction (XRPD) peak positions. Claim scope is tightly anchored to the dose regimen and the XRPD signature of the solid form. Outside those parameters, infringement risk decreases even if the pharmacological outcome is the same.
What does US Patent 11,020,382 claim protection cover for sickle cell disease?
Direct answer: The patent covers administering an orally dosed crystalline solvate “Compound 1” to increase hemoglobin and treat sickle cell disease, with a required dose (about 1500 mg once daily) and required XRPD peak locations (Cu Kα).
Claim 1 scope (treatment method)
- Disease/need: “treating sickle cell disease in a human patient in need thereof”
- Action: “administering to the patient Compound 1”
- Route: oral
- Dose regimen: about 1500 mg once daily
- Solid-state limitation: “Compound 1 is in a crystalline ansolvate form characterized by” XRPD peaks at:
- 13.37° 2θ (±0.2°)
- 14.37° 2θ (±0.2°)
- 19.95° 2θ (±0.2°)
- 23.92° 2θ (±0.2°)
- measured with Cu Kα radiation
Claim 2 scope (hemoglobin increase method)
- Mirrors Claim 1 on drug identity, oral route, dose regimen, and XRPD-defined crystalline ansolvate form
- The therapeutic purpose is framed as “increasing hemoglobin to treat sickle cell disease.”
Practical implication: Both claims are composition/solid-form-plus-regimen methods. The XRPD signature is a gating element. If a competitor uses the same therapeutic agent but a different solid form or different dose regimen, the claims as written may not read.
How strong are the claim limitations based on dose and XRPD peaks?
Direct answer: The dose and XRPD constraints make the claim set narrow and provide clear non-infringement design-around pathways using different dosing or different crystalline forms.
Dose constraint: “about 1500 mg once daily”
- “About” creates some latitude, but still anchors the claim to a narrow regimen centered on 1500 mg daily.
- Typical design-around vectors (conceptual, not legal advice) include:
- changing daily dose materially away from 1500 mg
- splitting into different dosing frequency (if “once daily” is not met)
- using different exposure profiles that avoid “about 1500 mg once daily”
Solid-state constraint: “crystalline ansolvate form” defined by XRPD peaks
- The crystalline ansolvate is not defined by chemical name in the excerpt; it is defined by XRPD peak locations.
- Each peak has a tolerance of ±0.2° 2θ, which matters for infringement analysis:
- A competitor must hit or fall inside each of the specified peak ranges.
- If even one peak is missing or shifted beyond the tolerance, claim coverage may fail.
Measurement constraint: “Cu Kα radiation”
- XRPD instrumentation and radiation source can affect reported 2θ values and peak indexing.
- The claim explicitly requires Cu Kα, creating another gating constraint.
What is the infringement risk for generic or alternative formulations of Compound 1?
Direct answer: Infringement hinges on whether the accused product is (a) the same “Compound 1” and (b) dosed orally at about 1500 mg once daily and (c) is the specific crystalline ansolvate solid form with the XRPD signature.
Risk drivers
- Same solid form: If a generic or alternative manufacturer uses the same XRPD-defined crystalline ansolvate, solid-form risk increases.
- Same regimen: If dosing is “about 1500 mg once daily,” method claims become more difficult to design around.
- Target endpoint: Claim 2 recites increasing hemoglobin, but Claim 1 does not require hemoglobin as an element. That means any sickle cell treatment administration using the claimed regimen and solid form can implicate Claim 1 even if hemoglobin rise is not separately measured as an element.
Risk reducers
- Different crystalline form: Using a different polymorph, solvate, hydrate, or amorphous form can move the XRPD peaks outside the listed windows.
- Different dose or dosing frequency: Avoiding “about 1500 mg once daily” reduces claim fit.
- Different radiation/source/testing approach: If peak identification fails under the claimed Cu Kα conditions, the XRPD-defined limitation may not be satisfied.
What prior art or prosecution history issues usually matter for claims like these?
Direct answer: For XRPD-defined crystalline forms and regimen-limited methods, scope fights in litigation typically focus on whether the XRPD definition is adequately clear and whether alternative solids are distinguishable.
Clarity and definiteness of XRPD peaks
- XRPD-peak definitions are often argued as either:
- sufficiently objective (peak positions with tolerance and radiation source)
- or insufficiently definite if peak identity, measurement conditions, or reference patterns are disputed
- The excerpt includes peak positions with explicit tolerance and Cu Kα, which is typically more objective than open-ended “characterized by” language without numbers.
Enablement and written description
- If the patent describes only one crystalline form, a court may restrict coverage to that form.
- If the specification supports broad ranges or multiple solids tied to the same peak pattern, scope may expand.
“Crystalline ansolvate” versus “crystalline solvate”
- The claim excerpt explicitly uses “crystalline ansolvate form.” If specification uses terminology differently (e.g., solvates interconverting, dehydration states), claim interpretation can become central.
How does this patent fit into the broader US patent landscape for sickle cell disease solid-form oral therapies?
Direct answer: Method-of-use claims like these are usually surrounded by a tighter perimeter of:
- compound claims on the active ingredient (“Compound 1”)
- formulation or solid-form patents (crystalline forms, hydrates/solvates/ansolvates)
- method-of-treatment patents (hemoglobin raising, transfusion reduction, symptom reduction)
- dosing regimen patents (dose amount, frequency, titration schedules)
Because this excerpt only contains the two method claims, the landscape conclusion is limited to risk around this specific solid-form-and-dose method. The most relevant litigation/commercial risks are:
- whether a competing product uses the same crystalline ansolvate
- whether it is dosed at about 1500 mg once daily
- whether any FDA-level substitutions preserve the same solid form at administration time
What would a Paragraph IV challenge need to address against US 11,020,382?
Direct answer: A Paragraph IV notice challenging this patent would need to attack at least one of these elements:
- the asserted invalidity grounds (anticipation/obviousness) mapped to the method limitations, or
- the non-infringement mapping (product lacks the required XRPD peaks, lacks the claimed dose regimen, or is not the claimed compound/solid form).
Typical invalidity targets (mapped to claim structure)
- Prior art crystalline forms with the same XRPD peaks (or overlapping peaks within tolerances)
- Prior art dosing regimens administering the compound orally at ~1500 mg once daily for sickle cell disease
- Prior art methods that administer the solid and achieve hemoglobin increases or treat sickle cell disease
Typical non-infringement targets
- Different XRPD pattern beyond listed peak tolerances
- Alternative polymorph or solvated/hydrated form
- Dose and frequency deviations
When does US Patent 11,020,382 lose exclusivity?
Direct answer: Exclusivity timelines depend on the patent’s term, PTA, and any FDA exclusivity extensions. No filing dates, patent term adjustment, or pediatric exclusivity data are provided in the prompt; without those facts, an accurate expiration date cannot be produced.
What is the Orange Book status and FDA regulatory posture for this patent?
Direct answer: Orange Book listing status cannot be determined from the prompt because the drug name, NDC(s), FDA application number, and Orange Book entries are not provided.
Which companies face the highest generic entry and litigation risk?
Direct answer: Company-specific risk cannot be determined from the prompt because “Compound 1” is not identified by chemical name, trade name, NDA/ANDA/BLA application number, or Orange Book listing.
How does claim scope compare between Claim 1 and Claim 2?
Direct answer: Claim 1 is broader on the clinical endpoint (it requires treating sickle cell disease, not explicitly hemoglobin increase). Claim 2 adds hemoglobin increase framing, but it does not add independent limitations beyond the same drug, dose, route, and XRPD-defined solid form.
Endpoint comparison
- Claim 1: treating sickle cell disease (clinical treatment objective)
- Claim 2: increasing hemoglobin to treat sickle cell disease (explicit endpoint)
Scope impact
- If an accused product administers the claimed compound at the claimed dose and solid form, it can more readily satisfy Claim 1 without needing proof of hemoglobin rise as a strict element.
- Claim 2 may still be asserted based on evidence of hemoglobin increase in use, but the patent does not add extra pharmaceutical elements beyond the endpoint language.
What are the main design-around strategies against US 11,020,382?
Direct answer: Design-arounds cluster around breaking one of three claim pillars: (1) dose regimen, (2) XRPD-defined solid form, (3) meeting the required measurement condition.
1) Adjust dose and/or frequency
- Move away from “about 1500 mg once daily” or change frequency away from once daily.
2) Switch crystalline form
- Use a different polymorph/solvate/hydrate/amorophous state so XRPD peaks do not match the required Cu Kα peak positions within ±0.2° 2θ.
3) Break XRPD match under Cu Kα
- Ensure the product’s XRPD profile does not reproduce all four listed peaks at the required tolerances under Cu Kα conditions.
How many patents likely cover Compound 1’s solid-state and dosing features?
Direct answer: Cannot be quantified from the prompt. Patent counting requires a known drug identity, application references, and a search of US Patent and Trademark Office records and the Orange Book.
Key Takeaways
- US 11,020,382 protects method-of-treatment for sickle cell disease using an oral administration of Compound 1 at about 1500 mg once daily.
- The claims are solid-form limited: “crystalline ansolvate form” is defined by Cu Kα XRPD peaks at 13.37°, 14.37°, 19.95°, and 23.92° 2θ (±0.2°).
- Claim 1 and Claim 2 share the same drug, dose, route, and XRPD limitation; they differ mainly by endpoint framing (treatment vs hemoglobin increase).
- The strongest commercial risk for competitors is when products match both the dose regimen and the XRPD-defined crystalline ansolvate.
- Design-arounds are primarily available by changing dose/frequency and/or using a different crystalline solid that does not match the claimed XRPD signature.
FAQs
-
Can a product with the same active ingredient avoid US 11,020,382 by changing only the solid form?
If the alternative solid form does not match the claimed XRPD peak positions (Cu Kα, ±0.2° for each peak), it can avoid reading on the XRPD-defined limitation.
-
Does Claim 1 require proof of hemoglobin increase?
No. Claim 1 requires treating sickle cell disease; hemoglobin increase is explicitly required in Claim 2.
-
How critical is the “once daily” dosing requirement?
It is a gating element. Deviating from once-daily dosing can reduce claim fit even if total daily exposure is similar.
-
What happens if one XRPD peak is outside ±0.2° 2θ?
The XRPD-defined limitation may not be satisfied, reducing infringement risk because each peak is separately specified with a tolerance.
-
Is the measurement condition (Cu Kα) a meaningful limitation?
Yes. The claim requires Cu Kα XRPD peak positions, so XRPD profiles derived under different conditions can fail to satisfy the claimed limitation.
References
- US Patent 11,020,382, “Method for treating sickle cell disease…,” claims 1-2 (as provided in prompt).
